Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of JNT-517 in Phenylketonuria
NCT06628128Phase 3Recruiting
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Aug 2025
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of repinatrabit in phenylketonuria (PKU), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Number of Participants with Treatment-emergent Adverse Events. Started Aug 2025; status: recruiting.
02
Drugs
repinatrabit
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NCT06628128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06628128.